title: Obstacles and opportunities for targeting the effector T cell response in type 1 diabetes.
abstract: Autoreactive lymphocytes display a programmed set of characteristic effector functions and phenotypic markers that, in combination with antigen-specific profiling, provide a detailed picture of the adaptive immune response in Type 1 diabetes (T1D). The CD4+ T cell effector compartment (referred to as "Teff" in this article) has been extensively analyzed, particularly because the HLA genes most strongly associated with T1D are MHC class II alleles that form restriction elements for CD4+ T cell recognition. This "guilt by association" can now be revisited in terms of specific immune mechanisms and specific forms of T cell recognition that are displayed by Teff found in subjects with T1D. In this review, we describe properties of Teff that correlate with T1D, and discuss several characteristics that advance our understanding of disease persistence and progression. Focusing on functional disease-associated immunological pathways within these Teff suggests a rationale for next-generation clinical trials with targeted interventions. Indeed, immune modulation therapies in T1D that do not address these properties of Teff are unlikely to achieve durable clinical response.
authors.affiliation: Benaroya Research Institute at Virginia Mason, The University of Washington School of Medicine, Seattle, WA, USA. Electronic address: jbuckner@benaroyaresearch.org.
authors.forename: Jane H
authors.initials: JH
authors.lastname: Buckner
authors.affiliation: Benaroya Research Institute at Virginia Mason, The University of Washington School of Medicine, Seattle, WA, USA.
authors.forename: Gerald T
authors.initials: GT
authors.lastname: Nepom
mesh_terms: D056704:Adaptive Immunity; D000818:Animals; D001324:Autoantigens / Q000276:immunology; D015551:Autoimmunity; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology / Q000378:metabolism; D003131:Combined Modality Therapy; D003922:Diabetes Mellitus, Type 1 / Q000209:etiology* / Q000378:metabolism* / Q000628:therapy; D020022:Genetic Predisposition to Disease; D000949:Histocompatibility Antigens Class II / Q000235:genetics / Q000276:immunology; D006801:Humans; D007108:Immune Tolerance / Q000187:drug effects; D056747:Immunomodulation / Q000187:drug effects; D007167:Immunotherapy; D007515:Islets of Langerhans / Q000276:immunology / Q000378:metabolism; D058990:Molecular Targeted Therapy; D015398:Signal Transduction / Q000187:drug effects; D016176:T-Lymphocyte Subsets / Q000276:immunology* / Q000378:metabolism*
chemical_list: D001324:Autoantigens; D000949:Histocompatibility Antigens Class II
keywords: CD4 T cell; Genetic susceptibility; Immunomodulation; Type 1 diabetes